AIM IMMUNOTECH - PHASE 2 DURIPANC TOPLINE RESULTS EXPECTED IN Q1 2027; ADDITIONAL ANALYSES IN Q3 2027 - SEC FILING

Reuters · 5d ago

Please log in to view news